# **Special Issue**

# Extracellular Vesicles for Cancer Therapy

### Message from the Guest Editors

EVs are nano-sized lipid-bilayer-encapsulated particles that are released by practically all types of cells in the three domains of life. EVs carry several biologically active molecules from parental cells, including proteins, lipids, sugars, DNA and RNA, namely non-coding RNAs. Accumulating evidence demonstrates that EVs can act both locally and at distant sites through their ability to modulate tumor growth, invasion, angiogenesis, immune inhibition and establishment of pre-metastatic niches. In fact, EVs can circulate to distant organs and induce changes in the microenvironment to potentiate future metastatic spread through horizontally transferring molecular information. Moreover, their stability when circulating in different body fluids and ability to transfer bioactive molecules between cells indicates their potential for the design of new therapeutic approaches. This Special Issue aims to highlight the potential of utilizing EVs in new cancer therapies, covering their potential as therapeutic agents, due to their innate therapeutic properties, or even as engineered therapeutic vehicles for known drugs or vaccines.

### **Guest Editors**

### Dr. Ana Luísa Teixeira

Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP) & RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal

#### Dr. Mariana Morais

Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP) & RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal

## Deadline for manuscript submissions

closed (28 February 2025)



# **Pharmaceutics**

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/195324

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

